Wegovy weight loss pill gets UK approval

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved a tablet form of semaglutide for weight management on 11 June 2026^[1]. Sold under the Wegovy brand name, the tablet is the first oral GLP-1 receptor agonist authorised for weight loss in the UK. Until now, Wegovy has only been available as a once-weekly subcutaneous injection.

The approval covers adults with obesity (BMI of 30 or above) or those who are overweight (BMI between 27 and 30) with at least one weight-related comorbidity, when used alongside a reduced-calorie diet and increased physical activity^[1]. This is the same patient population covered by the injectable version, but the pill format removes the need for self-injection.

What was approved and how it is taken

The approved dosing schedule starts at 1.5 mg once daily and titrates upward through 4 mg and 9 mg, with at least one month at each step, to a maintenance dose of 25 mg once daily^[1]. Patients who are already receiving injectable Wegovy at the 2.4 mg weekly dose can transition directly to the 25 mg tablet without a titration period.

The tablet must be swallowed whole on an empty stomach after at least eight hours of fasting, with only a sip of water. No food, drink, or other oral medicines should be taken for at least 30 minutes afterwards^[1]. These requirements are the same as those for Rybelsus, the existing oral semaglutide product approved for type-2 diabetes, and exist because the absorption enhancer in the formulation (SNAC, sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) needs specific gastric conditions to work.

What the clinical trial showed

The MHRA approval was supported by the OASIS clinical programme. The OASIS 4 trial, published in the New England Journal of Medicine in September 2025, enrolled 307 adults without diabetes who had obesity or overweight with at least one weight-related comorbidity^[2].

Over 64 weeks, participants who took oral semaglutide 25 mg experienced a mean weight loss of 13.6% of body weight, compared with 2.2% in the placebo group. Among participants who stayed on treatment (the "on-treatment" analysis), mean weight loss was higher. More than three-quarters (76.3%) of participants on semaglutide lost at least 5% of their body weight, compared with 30.5% on placebo^[2][3].

Gastrointestinal side effects were the most commonly reported adverse events: 74% of participants in the semaglutide group experienced at least one GI event (primarily nausea, diarrhoea, and vomiting), compared with 42% in the placebo group^[2]. That pattern is consistent with what has been observed across the broader semaglutide trial programme, including the STEP and SUSTAIN studies for injectable formulations (for more on GI tolerability, see our review of GLP-1 and GI motility adverse events).

The EMA followed a similar path

The European Medicines Agency (EMA) had already recommended oral Wegovy for weight management across the EU and EEA on 22 May 2026, making it the first oral GLP-1 treatment authorised for this indication in Europe^[3]. In the US, the FDA approved oral Wegovy in December 2025, and the product has since been commercially available there. The UK approval brings British patients into the same regulatory position.

NHS availability is not confirmed yet

MHRA approval means the drug meets regulatory standards for safety, quality, and effectiveness. It does not mean the NHS will fund it immediately. The National Institute for Health and Care Excellence (NICE) has not yet published a technology appraisal for oral Wegovy, and until it does, NHS prescribing and reimbursement remain uncertain. The MHRA press release noted that patients seeking the tablet would initially need to obtain it through private prescriptions^[1].

NICE has previously appraised injectable Wegovy for weight management, so a similar process for the oral formulation is expected, but no timeline has been announced.

Why the pill format matters

Needle aversion is one of the documented barriers to GLP-1 uptake. Data from the oral Wegovy launch in the US showed that more than 80% of early prescriptions went to patients who had never used an injectable GLP-1 therapy^[4], suggesting the pill format reaches a population that injectables did not. Whether the same pattern holds in the UK, where prescribing pathways and cost structures differ, remains to be seen.

The oral formulation also diversifies the supply chain. Tablet manufacturing uses different equipment and facilities than prefilled pen assembly, which could help reduce the supply shortages that have intermittently affected injectable semaglutide products in both the UK and the EU.

What we do not know yet

Several questions remain open. How oral Wegovy will be priced for UK private prescriptions has not been announced. Whether NICE will appraise it as a separate product or as a line extension of the existing injectable Wegovy appraisal is unclear. Long-term adherence data beyond the 64-week OASIS 4 timeframe is not yet available for the oral formulation, though the broader semaglutide evidence base (including the STEP-4 extension showing weight regain after discontinuation of injectable semaglutide) suggests that sustained treatment will be necessary for sustained effect.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making any decisions about weight management treatments.